Connect with us


The Spanish company Cebiotex is looking for private funding

The Spanish biotech company Cebiotex has opened a financing round. The company hopes to use the economic resources obtained to reach the second clinical phase of its drug development. Its drug CEB-01 helps surgeons to obtain better results in their oncological surgical interventions. Since its creation, the company has obtained more than $4.72 million (€4 million) in financing.



Cebiotex is looking for private funding. The Spanish startup, specialized in the development of products for the treatment of tumors, has opened a financing round of more than $589,000 (€500,000) through Capital Cell. 

The objectives of this round plus other funds that the company may receive later, and which the company does not rule out, are to complete phase I clinical trials with nine adult patients, to start a pediatric research plan, to begin the second clinical phase with liposarcoma patients and to scale up productivity, among others. In the future, the company is confident that it will be able to obtain orphan drug designation from the U.S. Drug Enforcement Agency (FDA). 

Cebiotex is a spin-off from the Hospital Sant Joan de Déu Barcelona and the Polytechnic University of Catalonia. The company is focused on the development of its biotechnology platform, a biocompatible and biodegradable biomembrane for local drug administration. Its drug CEB-01 helps surgeons to obtain better results in their oncological surgical interventions.  

Read more details about the company Cebiotex and its current crowdfunding campaign with the born2Invest mobile app. Our team of experienced journalists bring you the latest business news in the world, so you don’t lose time scrolling the internet. Download the Born2Invest mobile app for free and stay on top of everything that matters to you.

Cebiotex has obtained more than $4.72 million (€4 million) in funding since its foundation in 2012 

Cebiotex is a company founded in 2012 as a result of research carried out by its founders, which demonstrated the possibility of bringing to market a new technological solution to the problem of recurrent tumor growth after surgery. Since its creation, the company has obtained more than $4.72 million (€4 million) in financing. 

This research was born from the team’s ambition to prevent deaths from childhood cancer. In children, this disease is relatively rare, but it is very poorly served by the industry, as only four new pharactics against pediatric cancer have been approved in the last forty years. Soft tissue sarcomas (STS) are rare cancers with a very low survival rate and high occurrence. They lead to death in half of all cases and the average survival is only fourteen to seventeen months.

CEB-01 is capable of gradually releasing very high doses in a very localized manner but within the therapeutic range of SN-38. SN-38 is the active metabolite of the chemotherapy drug Irinotecan, a widely used product whose main problem lies in its high toxicity, which causes side effects of chemotherapy treatments. 

The company is led by Joan Beltrán, former director of companies such as Punto Blanco or Courtels

The company is led by Joan Beltrán, its founder and CEO. The manager is an engineer in machinery and technical fabrics for the aeronautical, automotive, renewable energy and biomedical industries. Beltrán has been a member of the board of directors in companies such as Courtels International Fabrics (United Kingdom), Penn Elastic (Germany), Punto Blanco, Relats and Indesmalla (Spain).


(Featured image by Daria Shevtsova via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.